Also from this source


You just read:

BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

News provided by

BridgeBio Pharma

Jan 30, 2018, 08:00 ET